Landsberg Bennett & Dubbaneh LLC Decreases Holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Landsberg Bennett & Dubbaneh LLC trimmed its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 1.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,381 shares of the exchange traded fund’s stock after selling 727 shares during the period. SPDR S&P Biotech ETF comprises 1.1% of Landsberg Bennett & Dubbaneh LLC’s investment portfolio, making the stock its 18th largest position. Landsberg Bennett & Dubbaneh LLC owned 0.12% of SPDR S&P Biotech ETF worth $4,234,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in XBI. Intellectus Partners LLC increased its stake in SPDR S&P Biotech ETF by 1.1% in the 2nd quarter. Intellectus Partners LLC now owns 12,779 shares of the exchange traded fund’s stock worth $1,121,000 after purchasing an additional 142 shares during the period. Capital Investment Counsel Inc increased its stake in SPDR S&P Biotech ETF by 3.7% in the 2nd quarter. Capital Investment Counsel Inc now owns 4,211 shares of the exchange traded fund’s stock worth $369,000 after purchasing an additional 150 shares during the period. Brown Advisory Inc. increased its stake in SPDR S&P Biotech ETF by 2.0% in the 2nd quarter. Brown Advisory Inc. now owns 8,423 shares of the exchange traded fund’s stock worth $739,000 after purchasing an additional 167 shares during the period. Sunbelt Securities Inc. increased its stake in SPDR S&P Biotech ETF by 6.4% in the 2nd quarter. Sunbelt Securities Inc. now owns 3,029 shares of the exchange traded fund’s stock worth $266,000 after purchasing an additional 181 shares during the period. Finally, Private Advisor Group LLC increased its stake in SPDR S&P Biotech ETF by 1.1% in the 2nd quarter. Private Advisor Group LLC now owns 18,230 shares of the exchange traded fund’s stock worth $1,599,000 after purchasing an additional 204 shares during the period.

SPDR S&P Biotech ETF stock traded up $1.10 during trading hours on Friday, reaching $77.15. The company had a trading volume of 439,348 shares, compared to its average volume of 4,732,436. The company has a 50-day moving average price of $79.59 and a 200 day moving average price of $83.99. SPDR S&P Biotech ETF has a 12-month low of $64.38 and a 12-month high of $93.87.

The business also recently declared a — dividend, which was paid on Wednesday, September 25th. Shareholders of record on Monday, September 23rd were paid a $0.0032 dividend. The ex-dividend date of this dividend was Friday, September 20th. This represents a yield of 0.1%.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Further Reading: G-20

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.